Financial terms include $40 million upfront for four programs, expansion options, and opt-out economics up to $535 million per program plus low double-digit royalties, totaling up to $2.1 billion.

In addition, fear and apprehension about genetic sampling and invasive tissue collection need to be taken into account and ...

Antibody therapeutics are laboratory-made proteins designed to work like the body's natural antibodies. They are widely used ...

In December, The Conversation hosted a webinar on AI's revolutionary role in drug discovery and development. Science and ...

AlphaFold, which predicts three-dimensional, bioactive forms of a protein, has millions of sequences and a couple of hundred thousand structures. It can tell you, based on a particular pattern, what ...

Nobel laureate Sir Michael Houghton and colleagues at Applied Pharmaceutical Innovation (API) outline how rigorous early ...

Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a dual hub centered in the United States and China, according to new research ...

The chemistry is powered by an LED lamp that triggers a self-sustaining chain reaction, forging new carbon–carbon bonds under mild conditions without toxic or expensive chemicals. Credit: Nordin Ćatić ...

Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) Receipt of previous ...

Many challenges face developers of drugs for rare diseases, including the small number of patients available for clinical trials, genotypic and phenotypic diversity within a disorder, poorly ...